Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry

[1]  J. Garcia-conde,et al.  Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group , 1997, Bone Marrow Transplantation.

[2]  S. Horning,et al.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.

[3]  S. Horning,et al.  Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. , 1997, Blood.

[4]  D. Zelterman,et al.  Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[6]  G. Bonadonna,et al.  Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Chan,et al.  Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Neuberg,et al.  Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Niland,et al.  Clonal Karyotypic Hematopoietic Cell Abnormalities Occurring After Autologous Bone Marrow Transplantation for Hodgkin's Disease and Non-Hodgkin's Lymphoma , 1994 .

[10]  J. Neglia,et al.  Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. , 1994, Blood.

[11]  J. Armitage,et al.  Autologous transplantation for Hodgkin's disease: coming of age? , 1994, Blood.

[12]  D. Reece,et al.  Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.

[13]  A. Hagenbeek,et al.  A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Moreau,et al.  Early intensive therapy with autotransplantation for high-risk Hodgkin's disease. , 1993, Leukemia & lymphoma.

[15]  C. Gisselbrecht,et al.  Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients. , 1993, International journal of radiation oncology, biology, physics.

[16]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[17]  R. Chopra,et al.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.

[18]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[19]  K. Maclennan,et al.  LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Hillner,et al.  The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Bacigalupo,et al.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. , 1991, Bone marrow transplantation.

[22]  E. Jaffe,et al.  Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Donnan,et al.  A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. , 1991, European journal of cancer.

[24]  A. Santoro,et al.  Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  R. Hoppe.  Development of effective salvage treatment programs for Hodgkin's disease: an ongoing clinical challenge. , 1991, Blood.

[26]  B. Clarkson,et al.  Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Armitage,et al.  Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Rossi,et al.  HODGKIN'S DISEASE PROGNOSIS: A DIRECTLY PREDICTIVE EQUATION , 1988, The Lancet.

[29]  M. Tucker,et al.  Risk of second cancers after treatment for Hodgkin's disease. , 1988, The New England journal of medicine.

[30]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.

[31]  E. Thomas.  High-dose therapy and bone marrow transplantation. , 1985, Seminars in oncology.

[32]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[33]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .